A
Annelies Wilder-Smith
Researcher at University of Bern
Publications - 369
Citations - 20757
Annelies Wilder-Smith is an academic researcher from University of Bern. The author has contributed to research in topics: Dengue fever & Dengue vaccine. The author has an hindex of 56, co-authored 349 publications receiving 16341 citations. Previous affiliations of Annelies Wilder-Smith include Boston Children's Hospital & Heidelberg University.
Papers
More filters
Journal ArticleDOI
The reproductive number of COVID-19 is higher compared to SARS coronavirus.
TL;DR: The authors' review found the average R0 for 2019-nCoV to be 3.28, which exceeds WHO estimates of 1.4 to 2.5, and is higher than expected.
Journal ArticleDOI
Epidemiology of dengue: past, present and future prospects.
TL;DR: The objective of this paper is to review historical and current epidemiology of d Dengue worldwide and reflect on some potential reasons for expansion of dengue into the future.
Journal ArticleDOI
The pandemic of social media panic travels faster than the COVID-19 outbreak.
Anneliese Depoux,Anneliese Depoux,Sam Martin,Sam Martin,Emilie Karafillakis,Emilie Karafillakis,Raman Preet,Raman Preet,Annelies Wilder-Smith,Annelies Wilder-Smith,Heidi J. Larson,Heidi J. Larson +11 more
TL;DR: The creation of an interactive platform and dashboard to provide real-time alerts of rumours and concerns about coronavirus spreading globally would enable public health officials and relevant stakeholders to respond rapidly with a proactive and engaging narrative that can mitigate misinformation.
Journal ArticleDOI
Can we contain the COVID-19 outbreak with the same measures as for SARS?
TL;DR: COVID-19 differs from SARS in terms of infectious period, transmissibility, clinical severity, and extent of community spread, but even if traditional public health measures are not able to fully contain the outbreak of CO VID-19, they will still be effective in reducing peak incidence and global deaths.
Journal ArticleDOI
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin,Melissa M. Higdon,Laith J. Abu-Raddad,Nick Andrews,Rafael Araos,Yair Goldberg,Michelle J. Groome,Amit Huppert,Katherine L. O’Brien,Pete Smith,Annelies Wilder-Smith,Scott L. Zeger,Maria Deloria Knoll,Minal Patel +13 more
TL;DR: COVID-19 vaccine efficacy or effectiveness against severe disease remained high, although it did decrease somewhat by 6 months after full vaccination, and the decrease is likely caused by, at least in part, waning immunity.